CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
CRISPR Therapeutics AG (CRSP) reported a Q3 loss of $1.01 per share, which was better than the Zacks Consensus Estimate of a $1.33 loss. However, the company lagged in revenue estimates.
November 05, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CRISPR Therapeutics reported a Q3 loss of $1.01 per share, better than expected but missed revenue estimates.
CRISPR Therapeutics' Q3 loss was smaller than expected, which is positive, but missing revenue estimates could offset this. The mixed results may lead to neutral short-term stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100